Rigel Pharmaceuticals submits NDA to FDA for Fostamatinib to treat chronic ITP

Rigel Pharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for an oral investigational drug candidate, Fostamatinib, for the treatment of chronic and persistent immune thrombocytopenia (ITP).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news